Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
Aardvark Therapeutics (NASDAQ: AARD), a clinical-stage biopharmaceutical company developing small-molecule therapeutics for metabolic diseases, has granted inducement stock options to two new employees. The grants, made between July 8-14, 2025, consist of options to purchase 10,372 shares of common stock.
The options were granted under the company's 2025 Inducement Equity Incentive Plan at exercise prices of $13.04 and $12.11, matching the closing prices on the respective grant dates. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly at 1/48th of the total shares.
Aardvark Therapeutics (NASDAQ: AARD), un'azienda biofarmaceutica in fase clinica che sviluppa terapie a piccola molecola per malattie metaboliche, ha concesso opzioni azionarie di incentivo a due nuovi dipendenti. Le concessioni, effettuate tra l'8 e il 14 luglio 2025, consistono in opzioni per l'acquisto di 10.372 azioni ordinarie.
Le opzioni sono state concesse nell'ambito del Piano di Incentivi Azionari 2025 dell'azienda, con prezzi di esercizio di 13,04 $ e 12,11 $, corrispondenti ai prezzi di chiusura nelle rispettive date di concessione. Le opzioni matureranno in un periodo di quattro anni, con il 25% che matura dopo un anno e il resto che matura mensilmente in quote pari a 1/48 del totale delle azioni.
Aardvark Therapeutics (NASDAQ: AARD), una empresa biofarmacéutica en etapa clínica que desarrolla terapias de pequeñas moléculas para enfermedades metabólicas, ha otorgado opciones de acciones como incentivo a dos nuevos empleados. Las concesiones, realizadas entre el 8 y el 14 de julio de 2025, consisten en opciones para comprar 10,372 acciones ordinarias.
Las opciones se concedieron bajo el Plan de Incentivos de Capital de Inducción 2025 de la empresa, con precios de ejercicio de $13.04 y $12.11, que coinciden con los precios de cierre en las fechas respectivas de la concesión. Las opciones se consolidarán durante cuatro años, con un 25% que se consolida después de un año y el resto que se consolida mensualmente en 1/48 del total de acciones.
Aardvark Therapeutics (NASDAQ: AARD)는 대사 질환을 위한 소분자 치료제를 개발하는 임상 단계의 바이오제약 회사로, 두 명의 신입 직원에게 유인 주식 옵션을 부여했습니다. 2025년 7월 8일부터 14일 사이에 부여된 이 옵션은 10,372주의 보통주를 매수할 수 있는 권리입니다.
이 옵션은 회사의 2025년 유인 주식 인센티브 계획에 따라 부여되었으며, 행사 가격은 각각 부여일의 종가인 $13.04 및 $12.11입니다. 옵션은 4년에 걸쳐 베스팅되며, 1년 후 25%가 베스팅되고 나머지는 매월 전체 주식의 1/48씩 베스팅됩니다.
Aardvark Therapeutics (NASDAQ : AARD), une société biopharmaceutique en phase clinique développant des thérapies à petites molécules pour les maladies métaboliques, a accordé des options d'achat d'actions incitatives à deux nouveaux employés. Les attributions, réalisées entre le 8 et le 14 juillet 2025, consistent en des options d'achat de 10 372 actions ordinaires.
Les options ont été accordées dans le cadre du Plan d'Incitation en Actions 2025 de la société, avec des prix d'exercice de 13,04 $ et 12,11 $, correspondant aux cours de clôture aux dates respectives d'attribution. Les options seront acquises sur une période de quatre ans, avec 25 % acquis après un an et le reste acquis mensuellement à raison de 1/48 du total des actions.
Aardvark Therapeutics (NASDAQ: AARD), ein biopharmazeutisches Unternehmen in der klinischen Phase, das kleine Molekültherapeutika für Stoffwechselerkrankungen entwickelt, hat zwei neuen Mitarbeitern Anreizaktienoptionen gewährt. Die Zuteilungen, die zwischen dem 8. und 14. Juli 2025 erfolgten, umfassen Optionen zum Kauf von 10.372 Stammaktien.
Die Optionen wurden im Rahmen des Inducement Equity Incentive Plans 2025 des Unternehmens zu Ausübungspreisen von 13,04 $ und 12,11 $ gewährt, die den Schlusskursen an den jeweiligen Zuteilungstagen entsprechen. Die Optionen werden über vier Jahre erworben, wobei 25 % nach einem Jahr und der Rest monatlich mit 1/48 der Gesamtaktienanteile vesten.
- None.
- None.
SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics for the treatment of metabolic diseases, today announced that between July 8-14, 2025, two new employees were granted inducement awards consisting of stock options to purchase an aggregate of 10,372 shares of common stock.
Each option was granted pursuant to the Aardvark Therapeutics, Inc. 2025 Inducement Equity Incentive Plan, and was granted as an inducement material to each employee’s employment with Aardvark in accordance with Nasdaq Listing Rule 5635(c)(4).
The exercise price of each option is equal to the closing price of Aardvark’s common stock on the date of grant of the applicable option, or
About Aardvark Therapeutics, Inc.
Aardvark is a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi Syndrome and metabolic diseases. Recognizing hunger (the discomfort from not having eaten recently) is a distinct neural signaling pathway separate from appetite (the reward-seeking, desirability of food). Our programs explore therapeutic applications in hunger-associated indications and potential complementary uses with anti-appetite therapies. Our lead compound, oral ARD-101, is in Phase 3 clinical development for the treatment of hyperphagia associated with PWS, a rare disease characterized by insatiable hunger. ARD-101 is also being studied in hypothalamic obesity. Aardvark is also developing ARD-201, a fixed-dose combination of ARD-101 with a DPP-4 inhibitor, with a goal of addressing some of the limitations of currently marketed GLP-1 therapies for the treatment of obesity and obesity-related conditions. For more information, visit aardvarktherapeutics.com.
Contact:
Carolyn Hawley, Inizio Evoke Comms
(619) 849-5382
Carolyn.hawley@inizioevoke.com
FAQ
What inducement grants did Aardvark Therapeutics (AARD) announce in July 2025?
What is the vesting schedule for Aardvark Therapeutics' (AARD) July 2025 inducement grants?
Why did Aardvark Therapeutics (AARD) issue these stock options in July 2025?
What is Aardvark Therapeutics' (AARD) main business focus?
